Blood cancers account for 10% of all new cancer diagnoses in France each year, encompassing a diverse group of diseases that affect white blood cells, red blood cells, or platelets, according to public health data. September marks an annual nationwide awareness campaign dedicated to blood cancers, mirroring the focus of October Rose for breast cancer, to highlight the critical importance of early screening and ongoing research.
Understanding Blood Cancers and Diagnostic Challenges
Blood cancers comprise several distinct pathologies, including leukemias, lymphomas, and myelomas, which originate in the bone marrow or lymph nodes. Because these conditions manifest through a wide variety of symptoms, obtaining a prompt and accurate diagnosis can prove difficult for clinicians, according to medical specialists at the University Hospital of Strasbourg (CHU de Strasbourg). Patients often experience vague or overlapping symptoms, which can delay detection.
Dr. Blandine Guffroy, a hematologist at CHU de Strasbourg, notes that these malignancies are frequently unfamiliar to the general public, leading to delayed medical evaluation. Persistent back pain, for instance, serves as a symptom of myeloma, while swollen lymph nodes require careful monitoring. Dr. Guffroy advises individuals to monitor the evolution of persistent symptoms and consult a primary care physician promptly to preserve treatment windows and maximize chances of recovery.
Therapeutic Innovations at CHU de Strasbourg
As a recognized regional reference center in eastern France, CHU de Strasbourg treats 1,000 patients with blood cancers annually. Professor Luc-Matthieu Fornecker, head of the hematology department at the hospital, emphasizes that the field has undergone a complete transformation over the past 10 to 15 years. Advanced treatment strategies increasingly allow physicians to bypass traditional chemotherapy and instead harness the patient’s own immune system to combat malignant cells, according to Professor Fornecker.
The process involves extracting healthy white blood cells from a patient's bloodstream, sending them to specialized pharmaceutical laboratories for genetic alteration, and reinfusing them. Once reintroduced, these modified cells recognize and destroy cancerous cells.
Patient Experiences with Experimental Treatments
Clinical advancements offer tangible hope for patients facing advanced or aggressive forms of the disease. Mélissa, diagnosed with lymphoma in 2021, underwent a bone marrow transplant followed by an experimental treatment protocol that successfully brought her into remission. Reflecting on her medical journey, she credits the precise timing and availability of innovative therapies for saving her life.
Facilities equipped to perform advanced cellular extraction remain specialized. CHU de Strasbourg stands as one of only two medical establishments in the Grand Est region equipped with the specialized technology required to extract healthy white blood cells for these sophisticated therapies, underpinning the region’s clinical capacity against hematological malignancies.
Related reading